101. PET monitoring of liver directed selective internal radionuclide therapy for metastatic gastro-oesophageal cancer
- Author
-
Dale L. Bailey, Stephen Clarke, Bob T. Li, and Adrian Lee
- Subjects
Male ,medicine.medical_specialty ,Esophageal Neoplasms ,medicine.medical_treatment ,Article ,030218 nuclear medicine & medical imaging ,Gastro oesophageal cancer ,03 medical and health sciences ,0302 clinical medicine ,FOLFOX ,Stomach Neoplasms ,Positron Emission Tomography Computed Tomography ,medicine ,Humans ,Yttrium Radioisotopes ,Aged ,Chemotherapy ,business.industry ,General Medicine ,medicine.disease ,digestive system diseases ,Oxaliplatin ,Peripheral neuropathy ,Fluorouracil ,030220 oncology & carcinogenesis ,Positron-Emission Tomography ,Radionuclide therapy ,Adenocarcinoma ,Radiology ,Radiopharmaceuticals ,business ,medicine.drug - Abstract
A 74-year-old man with metastatic gastro-oesophageal adenocarcinoma involving coeliac lymph nodes and liver was treated with fluorouracil and oxaliplatin (FOLFOX) chemotherapy. Despite initial good response, Oxaliplatin was omitted after development of significant peripheral neuropathy. His subsequent imaging showed progression of disease, predominantly in the liver. Selective internal radionuclide therapy (SIRT–Yttrium-90 (90Y) resin microsphere radioembolisation) was chosen by the multidisciplinary team as the modality to target his dominant left hepatic lobar disease. 90Y is a β-particle emitter suitable for radionuclide therapy, which, until recently, was not thought to be able to provide images directly from the decay of the radionuclide.1 Pretreatment (18F) …
- Published
- 2016